;
Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: Nextech raises $40M for Oncology IV fund

    Nextech Invest Ltd. raised the first $40 million of its planned $100 million Oncology IV fund, which it expects to close in the next 12 months. The firm intends to invest in eight to 10 companies developing cancer …

    Published on 10/13/2014
  • FINANCIAL NEWS: Probiodrug sets IPO terms

    Probiodrug AG (Halle/Saale, Germany) set a price range for its proposed IPO on Euronext Amsterdam. The Alzheimer's company plans to sell 1.5 million shares at EUR 15.25-EUR 19. At the midpoint price of EUR 17.13, …

    Published on 10/10/2014
  • FINANCIAL NEWS: PTC raises $108.8M in follow-on

    PTC Therapeutics Inc. (NASDAQ:PTCT) added $108.8 million to its coffers with its second big follow-on of 2014, selling 3 million shares at $36.25 in a deal underwritten by Credit Suisse; Citigroup; Cowen; Deutsche Bank;…

    Published on 10/10/2014
  • FINANCIAL NEWS: AutoGenomics files for IPO

    AutoGenomics Inc. (Vista, Calif.) filed to raise up to $60 million in an IPO on NASDAQ underwritten by Stifel; Canaccord Genuity; and Cantor Fitzgerald. The IPO filing is the company's third attempt to go public. …

    Published on 10/8/2014
  • FINANCIAL NEWS: Histogenics files for IPO

    Histogenics Corp. (Waltham, Mass.) filed to raise up to $65 million in an IPO on NASDAQ underwritten by Cowen; Needham; Cannaccord Genuity; and BTIG. Histogenics' NeoCart is in Phase III testing to repair knee cartilage…

    Published on 10/8/2014
  • FINANCIAL NEWS: Levicept raises L10M series A

    Levicept Ltd. (Sandwich, U.K.) raised L10 million ($16 million) in a series A round with Advent Life Sciences, Gilde Healthcare and Index Ventures.The biotech's LEVI-04 (p75NTR-Fc) is in preclinical development to treat…

    Published on 10/7/2014
  • FINANCIAL NEWS: Magnus raises L15.5M for its asset bundle

    Magnus Life Science (London, U.K.), a new company housed at University College London, raised L15.5 million ($24.8 million) in seed funding from an unnamed European private equity investor. Magnus said it has five …

    Published on 10/7/2014
  • FINANCIAL NEWS: Proteon sets IPO terms

    Proteon Therapeutics Inc. (Waltham, Mass.) set a price range for its proposed IPO on NASDAQ. The company hopes to sell 4.7 million shares at $12-$14. At $13, Proteon would raise $61.1 million and be valued at $182.6 …

    Published on 10/7/2014
  • FINANCIAL NEWS: TVM closes Fund VII at $201.6M

    TVM Capital Life Science announced the final closing of its TVM Life Science Ventures VII at $201.6 million.Lead investors included Teralys Capital and Eli Lilly and Co. (NYSE:LLY). Also participating were Business …

    Published on 10/6/2014
  • FINANCIAL NEWS: Virobay, Xenon set IPO terms

    Virobay Inc. (Menlo Park, Calif.) and Xenon Pharmaceuticals Inc. (Burnaby, B.C.) both set terms for their proposed IPOs on NASDAQVirobay plans to sell 3.8 million shares at $12-$14. At $13, Virobay would raise $50 …

    Published on 10/6/2014
  • FINANCIAL NEWS: Dermira raises $125 million in upsized IPO

    Dermira Inc. (NASDAQ:DERM) shed $0.45 to $15.55 in its first day of trading after the dermatology company raised $125 million through the sale of 7.8 million shares at $16 in an IPO on NASDAQ. Concurrently, partner UCB …

    Published on 10/3/2014
  • FINANCIAL NEWS: Forbion raises EUR 92M toward FCF III

    Forbion Capital Partners has raised the first EUR 92 million ($116.6 million) of a planned EUR 150-EUR 200 million fund, named FCF III. The firm said the final close could be more than 12 months away, but it expects …

    Published on 10/3/2014
  • FINANCIAL NEWS: Portola prices $161.2M follow-on

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA) added $1.10 on Friday to close at $27.60 after announcing late Thursday that it had priced 6.2 million shares at $26 in a follow-on that it said is expected to close on Oct. 8.…

    Published on 10/3/2014
  • FINANCIAL NEWS: Vital goes back for $35M in follow-on

    Liver disease company Vital Therapies Inc. (NASDAQ:VTL) raised $35 million through the sale of 2 million shares at $17.50 in a follow-on underwritten by BofA Merrill Lynch; William Blair, Canaccord Genuity; and SunTrust…

    Published on 10/3/2014
  • FINANCIAL NEWS: Calithera raises $80M in IPO

    Calithera Biosciences Inc. (NASDAQ:CALA) fell $0.59 to $9.41 in its first day of trading on NASDAQ after it raised $80 million through the sale of 8 million shares at $10 on Thursday. The IPO, underwritten by Citigroup;…

    Published on 10/2/2014
  • FINANCIAL NEWS: Forward Pharma sets range for big IPO

    Forward Pharma A/S (Copenhagen, Denmark) amended its IPO on NASDAQ and now plans to sell 9.5 million ADSs at $20-$22. At the $21 midpoint, the company would raise $200 million and be valued at $941.6 million. It filed …

    Published on 10/2/2014
  • FINANCIAL NEWS: Radius raises $50.2M in follow-on

    Radius Health Inc. (NASDAQ:RDUS) raised $50.2 million through the sale of 2.75 million shares at $18.25 in a follow-on underwritten by Jefferies; Cowen; and Cantor Fitzgerald. The company proposed the offering in a …

    Published on 10/2/2014
  • FINANCIAL NEWS: Visterra raises $30M in series B

    Visterra Inc. (Cambridge, Mass.) raised $30 million in a series B round led by new investors Merck Research Labs Venture Fund; Vertex Venture Holdings Ltd.; and Temasek. New investor Cycad Group and existing investors …

    Published on 10/2/2014
  • FINANCIAL NEWS: Ebola companies rise on Texas news

    Shares of several Ebola plays settled back Wednesday from double-digit gains in after-hours trading on Tuesday's news the CDC and the Texas Department of State Health Services announced the first U.S. diagnosis of an …

    Published on 10/1/2014
  • FINANCIAL NEWS: FibroGen files for IPO

    FibroGen Inc. (San Francisco, Calif.) filed to raise up to $125 million in an IPO on NASDAQ underwritten by Goldman, Sachs; Citigroup; Leerink; RBC; Stifel; and William Blair. FibroGen's lead compound is roxadustat (FG-…

    Published on 10/1/2014
  • FINANCIAL NEWS: LSP raises EUR 80M toward Fund 5

    LSP-Life Sciences Partners has raised the first EUR 80 million ($101.4 million) of a planned EUR 150 million fund. The firm said it intends to invest its new Fund 5 in 10-15 private companies with "innovative medicines …

    Published on 10/1/2014
  • FINANCIAL NEWS: NantHealth completes $320M B round

    NantHealth, a subsidiary of Patrick Soon-Shiong's NantWorks LLC (Los Angeles, Calif.), raised $250 million from the Kuwait Investment Authority (KIA) in the final close of its series B, bringing to $320 million the …

    Published on 10/1/2014
  • FINANCIAL NEWS: S1 Biopharma files for IPO

    S1 Biopharma Inc. (New York, N.Y.) proposed to raise up to $40.3 million in an IPO on NASDAQ underwritten by MLV. The biotech's lead product is lorexys, an oral fixed-dose enteric formulation of bupropion and trazodone …

    Published on 10/1/2014
  • FINANCIAL NEWS: VBL prices second IPO attempt

    VBL Therapeutics Ltd. (NASDAQ:VBLT) raised $40 million through the sale of 6.7 million shares at $6 in an IPO underwritten by Deutsche Bank, JMP and Oppenheimer. This is the company's second attempt at an IPO. Its …

    Published on 10/1/2014
  • FINANCIAL NEWS: Ebola plays up after Texas diagnosis

    Post-market traders bid up prices of Ebola plays after the CDC and the Texas Department of State Health Services said a patient in a Texas hospital has been diagnosed with the infection. The agencies said the diagnosis…

    Published on 9/30/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993